Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study

BACKGROUND: Treatment-resistant depression (TRD) is a chronic illness requiring long-term treatment. Esketamine nasal spray (ESK) has been studied in several long-term trials of patients with TRD, including SUSTAIN-1 (NCT02493868) and SUSTAIN-3 (NCT02782104). This subgroup analysis of SUSTAIN-3 eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, Meredith, Wilkinson, Samuel T., Al Jurdi, Rayan K., Petrillo, Mary Pat, Zaki, Naim, Borentain, Stephane, Fu, Dong Jing, Turkoz, Ibrahim, Sun, Liping, Brown, Brianne, Cabrera, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439056/
https://www.ncbi.nlm.nih.gov/pubmed/37558912
http://dx.doi.org/10.1007/s40263-023-01026-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439056/
https://www.ncbi.nlm.nih.gov/pubmed/37558912
http://dx.doi.org/10.1007/s40263-023-01026-3

Ejemplares similares